Trial Profile
A Retrospective study to evaluate the risk factors and the association of Nivolumab induced thyroid dysfunction with the pre-existing thyroid autoimmunity in patients with advanced Solid tumours
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jun 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics
- 19 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology